We report a quantitative analytical methodology for prostate-specific antigen (PSA) mRNA, which is based on the coamplification of the target with a recombinant RNA internal standard (IS) using reverse transcriptasepolymerase chain reaction. PSA mRNA and the RNA IS contain the same primer recognition sites and generate amplification products that have identical sizes but differ in a 24-bp sequence located in the center of the molecule. Amplified sequences are labeled with biotin using a biotinylated upstream primer. The products are captured on streptavidin-coated microtiter wells and hybridized to specific probes labeled with the hapten digoxigenin. The hybrids are determined using alkaline phosphatase- 
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We report a quantitative analytical methodology for prostate-specific antigen (PSA) mRNA, which is based on the coamplification of the target with a recombinant RNA internal standard (IS) using reverse transcriptasepolymerase chain reaction. PSA mRNA and the RNA IS contain the same primer recognition sites and generate amplification products that have identical sizes but differ in a 24-bp sequence located in the center of the molecule. Amplified sequences are labeled with biotin using a biotinylated upstream primer. The products are captured on streptavidin-coated microtiter wells and hybridized to specific probes labeled with the hapten digoxigenin. The hybrids are determined using alkaline phosphatase-labeled anti-digoxigenin antibody and time- In clinical management of patients with prostate cancer, it is important to distinguish between organ-confined and metastatic disease because of the relevant therapeutic and prognostic implications. Organ-confined disease is potentially curable by radical prostatectomy, but once the disease has spread to distant sites, patients are offered systemic treatment aimed at retarding the progression of the malignancy. However, the ability of current staging techniques to detect metastases is poor, and as many as 25-30% of patients who undergo prostatectomy are found with metastatic disease subsequent to surgery (1) (2) (3) (4) . Detection of prostatic cells in peripheral blood may be an earlier indication of metastasis.
Reverse transcriptase polymerase chain reaction (RT-PCR) 3 provides highly sensitive detection of mRNA sequences and has been used widely for the study of gene expression in malignant and physiological states (5, 6) . In 1992 Moreno et al. (7) applied RT-PCR methodology to the detection of prostate-specific antigen (PSA) mRNA as a specific marker of circulating prostatic cells in patients with metastatic prostate cancer. In 1994 Katz et al. (8) first applied RT-PCR for PSA mRNA in the preoperative staging of prostate cancer patients (molecular staging). In recent years, the analytical sensitivity of the technique has been improved substantially by increasing the number of PCR cycles, using nested PCR, using hot-start PCR, or enhancing the detectability of the amplification products (4, 9 -13) . Several clinical studies have also been performed using peripheral blood (4, 9 -13) , lymph nodes (14) , or bone marrow (15, 16 ) from prostate cancer patients.
Most of the PSA mRNA assays reported previously have been qualitative; that is, they detect the presence or absence of the particular mRNA without referring to its quantity. This has produced considerable controversy regarding the usefulness of the RT-PCR test in staging prostate cancer. For example, highly sensitive RT-PCR protocols have led to the detection of PSA mRNA in the blood of healthy individuals and patients with hyperplasia (17) (18) (19) (20) . The ability of circulating tumor cells to cause metastasis is still controversial, and a relationship be-tween PSA mRNA concentration and metastatic potential has not been reported. Several reports have addressed the need for a quantitative assay for PSA mRNA (13, (17) (18) (19) .
The limited number of reported quantitative protocols for PSA mRNA have been based on the parallel amplification of PSA mRNA with the mRNA of ␤-actin, a housekeeping gene (21) (22) (23) . A crucial assumption of the entire procedure is that the housekeeping gene has an even rate of transcription and is independent of different degrees of cellular activation. However, it has been reported that ␤-actin mRNA concentrations increase with the malignant transformation of cells (24) . In addition, the efficiency of reverse transcription and amplification for PSA and ␤-actin mRNA may vary, thus limiting the usefulness of the technique in a clinical setting.
In this work, we developed a quantitative analytical methodology for PSA mRNA that is based on the coamplification of the target RNA with a recombinant RNA internal standard (IS). The IS has the same primer binding sequences as the PSA mRNA and both amplification products are the same size, differing only in a 24-bp centrally located sequence. The RT-PCR products are captured on microtiter wells and analyzed by two separate nonradioactive and highly sensitive hybridization assays, using specific probes.
Materials and Methods materials
The human prostate adenocarcinoma cell line, LNCaP, that expresses PSA mRNA was obtained from the American Type Culture Collection (ATCC CRL 1740) and grown in medium containing 900 mL of RPMI-1640 (with l-glutamine), 100 mL of fetal bovine serum, 1 mL of fungizone, 50 kIU of penicillin, and 50 mg of streptomycin per liter (all from Gibco Life Technologies). The Polymorphprep used to isolate healthy lymphocytes from whole blood, Moloney murine leukemia virus reverse transcriptase, and Trizol LS reagent were also from Gibco. T7 RNA polymerase, Sephadex G-25 columns (Nap-5), RNase inhibitor, and dNTPs were from Pharmacia LKB. The Wizard DNA purification kit and the RQ1 RNase-free DNase were from Promega. The NTPs, digoxigenin-11-2Ј-dUTP (Dig-dUTP), yeast tRNA, blocking reagent, the anti-Digalkaline phosphatase conjugate and terminal deoxynucleotidyl transferase were from Boehringer Mannheim. Streptavidin, pUC18 HaeIII digest, Tween-20, mineral oil, diethylpyrocarbonate, and spermidine were obtained from Sigma. A 10 mmol/L stock solution of diflunisal phosphate was prepared in 0.1 mol/L NaOH and stored at 4°C. Terbium chloride hexahydrate was from Aldrich. Opaque Microlite 2 polystyrene microtiter wells were from Dynatech. BDH supplied all other general chemicals.
The following oligonucleotide sequences were used in the course of this work: (i) 5Ј-(NH 2 
rna isolation
We sedimented 10 7 LNCaP cells by centrifugation for 2 min at 12000g and added 1 mL of Trizol LS reagent (25) . Total RNA was then isolated according to the manufacturer's instructions. RNA, precipitated with 2-propanol, was washed with 750 mL/L ethanol and redissolved in 20 L of diethylpyrocarbonate-treated water containing 37 units of RNase inhibitor.
Whole blood (5 mL), used for isolation of total RNA from healthy cells, was separated with Polymorphprep according to the manufacturer's instructions. Polymorphonuclear cells were washed once in phosphate-buffered saline (10 mmol/L sodium phosphate, 1.76 mmol/L potassium phosphate, 0.14 mol/L NaCl, and 2.7 mmol/L KCl solution, pH 7.4), pelleted and resuspended in 1 mL of phosphate-buffered saline. The cells were pelleted at 12000g for 2 min. Trizol LS reagent was then added, and total RNA isolation was carried out as described above for the LNCaP cells. The RNA concentration was determined by its absorbance at 260 nm with the Shimadzu UV-160 spectrophotometer.
synthesis of the rna is
A DNA template was first synthesized, starting with the recombinant plasmid pA75 (26) , which contains a 1.4-kb PSA cDNA insert. Two separate PCRs were set up to create two short products, A and B, each containing a newly introduced sequence of 24 bp. For PCR-A, we used oligonucleotides (u) and (a) as upstream and downstream primers, respectively ( 7 molecules of plasmid DNA, and 2.5 units of Taq polymerase. The mixtures were layered with mineral oil and placed in the 48-well PerkinElmer DNA thermal cycler. The primers were added to the mixture after the block temperature had reached 95°C. The cycling parameters were as follows: 95°C for 30 s, 55°C for 30 s, and 72°C for 1 min. After the completion of 30 cycles, the samples were incubated at 72°C for 10 min and cooled to 4°C. The products of PCR-A and PCR-B were 90 bp and 167 bp, respectively. Twenty-microliter aliquots of each product were electrophoresed on a 2% agarose gel, and the DNA was stained with ethidium bromide. The 90-bp and 167-bp bands were excised from the gel, and a small slice from each band was used in a PCR mixture similar to the one described above but containing no primers. The mixture was subjected to 40 cycles of denaturation (95°C, 1 min), annealing (55°C, 1 min), and extension (72°C, 2 min). Subsequently, 5 L of this reaction mixture was amplified for 30 cycles, using oligos (u) and (d) as upstream and downstream primers, respectively. The PCR conditions were as described above for the short fragments. This amplification produced a 233-bp recombinant DNA fragment.
The new DNA fragment was then fused to the T7 promoter through PCR to create a complete transcription unit. The PCR was carried out with oligonucleotides (T7-u) and (d) as upstream and downstream primers, respectively, and 1 L of a 100-fold dilution of the previous recombinant amplification product. The cycling protocol and PCR buffer were as described above for the short fragments, with an annealing temperature of 60°C instead of 55°C. The products of three amplifications were pooled and purified with the Wizard PCR preps DNA purification system according to the manufacturer's instructions. Through this process, excess primers were removed, and the desired product (DNA template with the T7 promoter) was concentrated in 50 L of water.
The 
labeling of primer and probes
The upstream primer (u) was synthesized with an amino group at the 5Ј end and was labeled with NHS-LC-biotin (Pierce). To 0.1 mL of primer (10 nmol) diluted in water, we added 20 L of 0.5 mol/L carbonate buffer, pH 9.1, and 56 L (5 mol) of NHS-LC-biotin dissolved in dimethyl sulfoxide. After a 2-h incubation at room temperature, the biotinylated primer was purified three times by size exclusion chromatography using Nap-5 columns. The purified primer solution was concentrated four times by lyophilization.
The probes p 1 and p 2 were tailed enzymatically with multiple Dig moieties. The tailing reactions were performed in a total volume of 20 L that consisted of 0.2 mol/L potassium cacodylate, 25 mmol/L Tris-HCl (pH 6.6), 0.25 g/L bovine serum albumin, 5 mmol/L CoCl 2 , 50 mol/L Dig-11-2Ј-dUTP, 0.5 mmol/L dATP, 25 U of terminal deoxynucleotidyl transferase, and 100 pmol of probe. The reactions were carried out at 37°C for 45 min and were then terminated by adding 2 L of 0.2 mol/L EDTA. The labeled probes were used without purification.
quantification of psa mRNA For reverse transcription, a solution (total volume, 12 L) containing 10 pmol of downstream primer (d), 1 g of total RNA (containing PSA mRNA), and 2 L of RNA IS working solution (prepared as described previously in this section) was heated for 5 min at 70°C and placed on ice. Then an 8-L aliquot of a buffer containing 125 mmol/L Tris (pH 8.3), 187.5 mmol/L KCl, 25 mmol/L dithiothreitol, 7.5 mmol/L MgCl 2 , 1.25 mmol/L of each dNTP, and 200 U of reverse transcriptase was added to the sample. The reaction was allowed to proceed for 1 h at 37°C, after which the reverse transcriptase was inactivated by heating at 95°C for 5 min and then chilling on ice. PCR was performed on a total volume of 100 L containing (final concentrations) 20 mmol/L ammonium sulfate, 75 mmol/L Tris-HCl (pH 8.8), 1 mL/L Tween-20, 2 mmol/L MgCl 2 , 50 mol/L dNTPs, 50 pmol of each of the biotinylated upstream primer (u) and the downstream primer (d), 2.5 U of polymerase (Ultratherm DNA polymerase, Bio/Can Scientific), and 8 L of the reverse transcription mixture. The hot-start protocol was followed, in which the mixture was heated to 95°C for 5 min, and then the primers were added. PCR was carried out for 33 cycles of denaturation at 95°C for 30 s, annealing (65°C, 30 s), and extension (72°C, 1 min). Finally, the mixtures were incubated at 72°C for 10 min and then cooled to 4°C until their analysis by hybridization.
For the hybridization assay, opaque polystyrene microtiter wells were coated overnight at room temperature with 50 L of 1.4 mg/L streptavidin diluted in phosphatebuffered saline. Before use, the wells were washed three times with wash solution (50 mmol/L Tris, pH 7.4, 0.15 mol/L NaCl, and 1 mL/L Tween-20) using the microtiter plate washer Model EAW II from SLT-Laboratory Instruments. Then 50 L of PCR product, diluted 10-fold in blocking solution (10 g/L blocking reagent in 0.1 mol/L maleic acid and 0.15 mol/L NaCl, pH 7.5), was pipetted into each of four wells and incubated with shaking for 30 min. The wells were then washed as above, and 50 L of a 0.2 mol/L NaOH solution was added. After a 20-min incubation, the DNA strand was removed by washing, as above. Each Dig-labeled probe, i.e., p 1 
Results and Discussion
The recombinant RNA IS was constructed by replacing a 24-bp sequence spanning the exon 2/exon 3 junction of the PSA mRNA (shown by the two vertical arrows in Fig.  1 ) with a new segment of equal size. This was accomplished by using PCR as a synthetic tool, as previously described (27) . The PSA cDNA was amplified with primers (u) and (a) (PCR-A). PCR-B used primers (b) and (d). Subsequently, products A and B were mixed and subjected to cycles of denaturation, annealing, and extension in the presence of DNA polymerase but without added primers. Because the 5Ј extensions of the fragments are complementary to each other, during the cycling process the two fragments act as primers leading to the joining of A and B and the production of the 233-bp fragment. This fragment was then fused to the T7 promoter (through PCR) and served as the template for synthesis of the RNA IS. After transcription and purification, the RNA IS was treated with DNase to degrade any traces of DNA template that may have been present. Amplification of RNA IS aliquots by PCR and analysis by hybridization gave no signal, confirming the absence of contamination from DNA template.
To verify the presence of the new 24-bp sequence in the RNA IS and to confirm that the amplification products from PSA mRNA and the RNA IS were distinguishable by hybridization, we performed RT-PCR on two samples containing PSA mRNA and the RNA IS. Each PCR product was then analyzed in triplicate by hybridization to both probes p 1 and p 2 . The signals obtained from amplified PSA mRNA assayed with probes p 1 and p 2 were 114 990 Ϯ 4646 and 1232 Ϯ 86, respectively. The amplified RNA IS tested with probes p 1 and p 2 gave signals of 2567 Ϯ 275 and 139 830 Ϯ 4494, respectively. Therefore, the amplified PSA mRNA binds exclusively to probe p 1 , whereas the RNA IS binds only to probe p 2 . The fluorescence signals obtained after testing each PCR product with the noncomplementary probe reflect the nonspecific binding of the probe and the alkaline phosphataselabeled anti-Dig antibody to the solid phase (typical readings for the assay blank). This experiment also confirmed that cross-hybridization between targets and probes did not occur and that the RNA IS solution was free of contamination from PSA mRNA and/or its amplification product (and vice versa).
The sensitivity and linear range of the two hybridization assays were established as follows. We first prepared a stock solution of biotinylated amplification product by Clinical Chemistry 44, No. 6, 1998 pooling several RT-PCRs of the PSA mRNA. The DNA concentration of the stock was determined by scanning densitometry of the negatives prepared from pictures of ethidium bromide-stained agarose gels. The pUC18 DNA fragments were used as calibrators. The Bio-Rad Model GS-670 imaging densitometer (Bio-Rad Laboratories) was used for quantification of the DNA bands. The Molecular Analyst, Ver. 1.0, software was used, and the dependence of ethidium bromide incorporation on the fragment size was taken into account. A stock solution of amplification product for the RNA IS was also prepared as above. After quantification, various dilutions of each stock solution were analyzed by hybridization to probe p 1 or p 2 . In Fig.  2 , the fluorescence (corrected for the background) is plotted vs the concentration of the amplified DNA. The background is defined as the fluorescence obtained when a sample containing no amplification product was assayed. Each data point represents the average of two assays. Concentrations as low as 4 pmol/L (200 attomoles/well) of amplification products from PSA mRNA and RNA IS were detected with signal-to-background ratios (S/B) of 1.5 and 3.0, respectively. The linear range extends up to 1000 pmol/L and 500 pmol/L, respectively. The hybridization assay for the IS was more sensitive than the assay for the target. The probes were designed with the same GC content and therefore, the hybrids are expected to have the same melting temperature. The difference in the calibration graphs of Fig. 2 is probably because of folding of the captured single-stranded target DNA (i.e., after the NaOH step), which might interfere with the hybridization.
The reproducibility (within-run) of the hybridization assay was tested by analyzing samples containing 31, 125, and 500 pmol/L of amplified DNA. The CVs were 4.2%, 5.2%, and 9%, respectively (n ϭ 5).
The ability of the proposed analytical system to quantitate PSA mRNA from a few PSA-expressing cells in the presence of total RNA from healthy cells was estimated by preparing mixtures containing total RNA representative of 4 to 3000 LNCaP cells in the presence of 1 g of total RNA from healthy cells (isolated from whole blood as described in Methods and Materials). A fixed amount of RNA IS was added into each sample. After reverse transcription and amplification, the products were analyzed by the two hybridization assays. The fluorescence obtained for the PSA mRNA and the RNA IS was plotted as a function of the number of LNCaP cells (Fig. 3) . The S/B ratios for PSA mRNA corresponding to 4 and 12 LNCaP cells were 1.6 and 2.5, respectively. The fluorescence corresponding to the RNA IS remained constant for small numbers of LNCaP cells but then decreased as the amount of PSA mRNA in the sample increased. This is because of the plateau phenomenon of PCR. When the amplification is in the exponential phase, the efficiency is constant. Because the same amount of RNA IS is used in every sample, the amount of amplified RNA IS, and therefore the signal, is relatively constant and independent of the starting amount of the PSA mRNA. However, as the PSA mRNA increases, the signal for IS decreases because of competition with the target RNA for amplification as well as the PCR plateau effect.
The amount of RNA IS added to each sample may The amplified DNA was end-labeled with biotin (through PCR), captured on streptavidin-coated wells, and hybridized to Dig-labeled probes p 1 and p 2 , respectively. Fluorescence is in arbitrary units. affect the sensitivity and the analytical range of the technique. If a large amount of IS is added, then small quantities of PSA mRNA will not be amplified enough to generate a signal. On the other hand, a small amount of RNA IS in the presence of relatively high PSA mRNA concentrations would be undetectable after amplification. In our study, the amount of IS was optimized empirically by testing serial dilutions of the stock, such that the amplification product gave a fluorescence signal that was in the middle of the linear range of the calibration curve for the hybridization assay. In Fig. 4 , the ratio, F/F IS of the fluorescence values obtained for the PSA mRNA and the RNA IS was plotted against the number of LNCaP cells. The data suggest that the quantitative assay is linear in the range of 4 to 3000 cells. Because only 40% of the reverse transcription mixture was amplified and only 1/20th of the PCR mixture was used for analysis, the fluorescence signal represents amplification product from PSA mRNA corresponding to Ͻ0.1 LNCaP cell.
To assess the overall reproducibility (between-run) of the quantitative RT-PCR, CV studies were carried out at three PSA mRNA concentrations in the presence of 1 g of healthy RNA. RT-PCRs for the three pools, containing different concentrations of PSA mRNA, were performed four times on different days. The CVs of the F/F IS ratios obtained from the three pools were 16.1%, 16.2%, and 14.2%. In addition, from the F/F IS ratios and the graph of Fig. 4 , it was estimated that the pools contained 31, 381, and 1626 cells, with CVs of 19.1%, 19.1%, and 17.0%, respectively.
The proposed analytical methodology for quantification of PSA mRNA has several advantages. First, the method is based on the use of a recombinant RNA IS that contains the same primer binding sites as the target RNA. Thus (in the absence of mispriming events of the RT primer to the considerably larger native RNA), any variation in the efficiency of the reverse transcription and/or the PCR step affects both RNAs equally, and the ratio of the analytical responses reflects the initial ratio of the two RNAs in the starting mixture. This is proven by the linearity and the reproducibility of the assays. Second, the PCR products are confirmed by hybridization assays performed in microtiter wells, thus avoiding electrophoresis and densitometry, as well as facilitating automation for use in the routine laboratory. Finally, timeresolved fluorometry offers the high sensitivity required for this type of analysis while eliminating the need for radioisotopic labeling of PCR products or probes.
In our opinion, the proposed method will find applications in the following areas: (a) to distinguish between clinically relevant and nonrelevant concentrations of PSA mRNA, the latter possibly occurring because of illegitimate transcription (28); (b) to provide information about the relation of PSA mRNA concentrations and recurrent disease after surgery; (c) as a powerful research tool in the study of the biology of prostate cancer and the metastatic process; and (d) PSA may be a new favorable prognostic indicator in female breast cancer, as has been found in recent years (29 -32) . In view of these findings, we expect that the assay may find application in the monitoring of nonprostatic diseases.
One drawback of the proposed quantitative assay for PSA mRNA is that it cannot distinguish if the increased mRNA concentration is because of a large number of PSA-expressing cells (containing small amounts of the particular mRNA) or to a small number of cells containing high amounts of PSA mRNA. This point should be taken into account in the clinical evaluation of the quantitative PCR assay. 
